Evidence map›Paper›PMID 28160550›Full record

ArticleOncotarget2017

Dysadherin specific drug conjugates for the treatment of thyroid cancers with aggressive phenotypes.

Samuel Jang, Xiao-Min Yu, Celina Montemayor-Garcia, Kamal Ahmed, Eric Weinlander, Ricardo V Lloyd, Ajitha Dammalapati, David Marshall, James R Prudent, Herbert Chen

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Samuel JangDepartment of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Xiao-Min YuDepartment of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Celina Montemayor-GarciaDepartment of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Kamal AhmedDepartment of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Eric WeinlanderDepartment of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Ricardo V LloydDepartment of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Ajitha DammalapatiDepartment of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
David MarshallCentrose LLC, Madison, WI, USA.
James R PrudentCentrose LLC, Madison, WI, USA.
Herbert ChenDepartment of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
University of Wisconsin–Madison · USCentrose (United States) · USUniversity of Alabama at Birmingham · US

Funding

Surgery Summer Research Experience for Medical StudentsT35DK062709 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI MEZRICH, JOSHUA D · 2006 to 2023
$870k
NIDDK NIH HHS T35 DK062709
6 · The paper itself

Abstract

backgroundEDC1 is a novel type of antibody-drug conjugate which binds and inhibits the Na,K-ATPase on the surface of cancer cells expressing dysadherin. The purpose of this study was to determine the expression of dysadherin in different types of thyroid carcinoma, and evaluate the therapeutic potential of EDC1 for thyroid carcinomas.

methodsThyroid tissues from 158 patients were examined for dysadherin expression and correlation with clinicopathological features. Thyroid cancer cell lines were examined for the expression of dysadherin and effective dose range of EDC1.

resultsOne in 53 benign thyroid tissues and 62% of thyroid cancers expressed dysadherin. All anaplastic and a majority of papillary thyroid cancers overexpressed dysadherin, while 25% of follicular thyroid cancers was found to be positive for dysadherin. Dysadherin expression significantly correlated with extrathyroidal extension and lymph node metastases in papillary thyroid cancer. Five of six human thyroid cancer cell lines analyzed expressed high levels of dysadherin. Of those cells lines sensitive to EDC1, half maximal effective concentrations (EC50) were observed to be between 0.125 nM and 1 nM.

conclusionsEDC1 showed selective inhibition of growth in thyroid cancer cells with moderate to high expression of dysadherin, thus could be a specific and effective treatment.

Indexed as

AdolescentAdultAgedAged, 80 and overFemaleHumansIon ChannelsMaleMembrane GlycoproteinsMicrofilament ProteinsMiddle AgedNeoplasm ProteinsPhenotypeThyroid NeoplasmsYoung AdultFXYD5 protein, humanIon ChannelsMembrane GlycoproteinsMicrofilament ProteinsNeoplasm Proteinsaggressive phenotypeantibody-drug conjugatedysadherinthyroid cancertreatment

Identifiers

PMID28160550
PMCPMC5421862
OpenAlexW2583782264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.